Zydus receives final approval from USFDA for Nitroglycerin Sublingual Tablets

Zydus Lifesciences Ltd. has received final approval from the USFDA to market Nitroglycerin Sublingual Tablets in the strengths of 0.3 mg, 0.4mg and 0.6mg (US RLD: Nitrostat Sublingual Tablets). Nitroglycerin Sublingual Tablets are used to relieve chest pain (angina) in people who have a certain heart condition (coronary artery disease). It may also be used before physical activities to help prevent chest pain. Nitroglycerin belongs to a class of drugs known as nitrates. Angina occurs when the heart muscle is not getting enough blood. This drug works by relaxing and widening blood vessels so blood can flow more easily to the heart. The drug will be manufactured at the group's formulation manufacturing facility at SEZ, Ahmedabad.

The group now has 329 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.

Shares of Zydus Lifesciences Ltd (formerly Cadila Healthcare Limited) was last trading in BSE at Rs. 359.85 as compared to the previous close of Rs. 343.85. The total number of shares traded during the day was 114489 in over 4430 trades.

The stock hit an intraday high of Rs. 363.00 and intraday low of 348.00. The net turnover during the day was Rs. 41053249.00.

Source : Equity Bulls

Keywords

ZydusLifesciences CadilaHealthcare INE010B01027 USFDA FinalApproval NitroglycerinSublingualTablets